Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
JY
The Joint Corp.
JYNT
Mkt Cap
$100.1M
Volume
45.51K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
JY
JYNT
JY
The Joint Corp.
JYNT
News
·
Strength Seen in Humana (HUM): Can Its 11.6% Jump Turn into More Strength?
Mkt Cap
$97.7M
Volume
45.51K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Strength Seen in Humana (HUM): Can Its 11.6% Jump Turn into More Strength?
Humana shares surged 11.6% to $431.87, driven by strong Medicare membership growth (up 20.7% YoY to 17.9 million members) and expansion of its CenterWell platform. However, the stock faces headwinds as consensus EPS estimates have been revised 2.7% lower over the past 30 days, and the company is expected to report a quarterly loss of $1.04 per share. The stock holds a Zacks Rank #3 (Hold) rating.
Zacks Investment Research · Oct 12, 2026
The Joint Corp. Signs Asset Purchase Agreement to Sell 22 Corporate Clinics in the Southeast and Delivers Notice to Terminate APA for 45 Clinics in California
The Joint Corp. signed an Asset Purchase Agreement to sell 22 corporate-owned clinics in the Southeast for $1.5 million to three buying groups, and delivered a notice to terminate a previous agreement for 45 clinics in California.
GlobeNewswire Inc. · Dec 11, 2025
The Joint Corp. Expects to Restate Full Year 2024 and First Quarter 2025 Financial Statements due to Overestimated Noncash Impairment Charges
The Joint Corp. announced plans to restate its 2024 and Q1 2025 financial statements due to overestimated noncash impairment charges, expecting to reduce net loss by $2.2 million and increase net income by $0.5 million.
GlobeNewswire Inc. · Jul 30, 2025
The Joint Chiropractic Takes the Top Spot Again as No. 1 in Chiropractic Services Franchises by Entrepreneur Magazine
The Joint Chiropractic has been named the top franchise in chiropractic services by Entrepreneur Magazine's Franchise 500, jumping 29 spots to rank No. 54 on the 2025 list.
Benzinga · Feb 13, 2025
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine - Zacks Investment Research
Valneva's single-dose Chikungunya vaccine, IXCHIQ, has received marketing authorization from the European Commission. This approval follows the FDA's nod in November 2023 and positions Valneva to protect European populations against Chikungunya outbreaks. The global Chikungunya vaccine market is expected to grow significantly, driven by rising medical needs and increased vaccine research and development.
Zacks Investment Research · Jul 8, 2024
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
Zacks Investment Research · Jul 2, 2024
National Vision (EYE) Gains Market Share Despite Macro Woes
National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.
Zacks Investment Research · Jul 1, 2024
Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch
Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.
Zacks Investment Research · Jun 28, 2024
Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health
Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.
Zacks Investment Research · Jun 27, 2024
Charles River (CRL) Inks CDMO Deal With Gates Institutes
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Zacks Investment Research · Jun 26, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
JY
JYNT
The Joint Corp.
Buy
Sell
Market
Limit
Soon
JYNT
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any JYNT yet.
Related Tickers
Earnings